	US 11,717,578 B2
	Undecylenic acid-based nanocarriers for targeted drug delivery
Clifford E. Larrabee, Cincinnati, OH (US); and Mary R. Warmin, Cincinnati, OH (US)
Assigned to University of Cincinnati, Cincinnati, OH (US)
Appl. No. 16/637,082
Filed by University of Cincinnati, Cincinnati, OH (US)
PCT Filed Aug. 9, 2018, PCT No. PCT/US2018/045912 § 371(c)(1), (2) Date Feb. 6, 2020, PCT Pub. No. WO2019/032771, PCT Pub. Date Feb. 14, 2019.
Claims priority of provisional application 62/542,898, filed on Aug. 9, 2017.
Prior Publication US 2020/0246483 A1, Aug. 6, 2020
Int. Cl. A61K 47/69 (2017.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 31/133 (2006.01); A61K 31/195 (2006.01); A61K 31/4453 (2006.01); A61K 31/4965 (2006.01); A61K 31/704 (2006.01); A61K 31/7068 (2006.01); B82Y 5/00 (2011.01)

CPC A61K 47/6907 (2017.08) [A61K 9/0019 (2013.01); A61K 31/133 (2013.01); A61K 31/195 (2013.01); A61K 31/4453 (2013.01); A61K 31/4965 (2013.01); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61P 35/00 (2018.01); B82Y 5/00 (2013.01)]

18 Claims

1. A targeted drug delivery system comprising a chemotherapeutic agent solubilized with undecylenic acid (UA)-based nanocarrier vesicles selected from polymeric UA-based nanocarrier vesicles, monomeric UA-based nanocarrier vesicles bonded to methoxy polyethylene glycol (mPEG), and polymeric UA-based nanocarrier vesicles bonded to mPEG, wherein the chemotherapeutic agent comprises at least one reactive oxygen species (ROS)-activated cytotoxic agent (RAC) and wherein the drug delivery system is formulated for intravenous injection or infusion.